Physician profile
Nina Statile
NPI 1144746793
$3,184.62
in general payments reported to CMS, 2019-2025
27 companies · $373 in 2025
The $373 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $330 · 2022: $888 · 2023: $900 · 2024: $694 · 2025: $373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,868 · Education: $98.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,868.17 |
| Education | $98.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $670.03 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $439.87 | 2021-2025 | Fasenra, Airsupra |
| Novo Nordisk INC | $338.86 | 2021-2022 | |
| Ars Pharmaceuticals Operations, INC. | $218.99 | 2025 | Neffy |
| Genzyme Corporation | $171.53 | 2023-2025 | |
| Astellas Pharma US INC | $134.67 | 2021-2023 | Veozah |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $132.95 | 2022 | |
| Glaxosmithkline, LLC. | $122.72 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Genentech USA, INC. | $119.05 | 2024 | Xolair |
| Idorsia Pharmaceuticals US INC | $117.21 | 2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $98.99 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.37 | 2021-2022 | |
| Amgen INC. | $64.20 | 2022-2025 | Otezla, Repatha, Tezspire |
| Lilly USA, LLC | $64.04 | 2022-2023 | Mounjaro |
| Novartis Pharmaceuticals Corporation | $53.41 | 2022-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $50.18 | 2021-2022 | |
| Exact Sciences Corporation | $44.66 | 2023 | Cologuard Collection Kit |
| Renalytix Ai, INC. | $36.99 | 2022 | |
| Pfizer INC. | $36.69 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $35.00 | 2021-2022 | |
| Csl Behring | $33.74 | 2024 | Haegarda |
| Currax Pharmaceuticals LLC | $31.75 | 2022-2023 | Contrave, Onzetra Xsail |
| Eisai INC. | $19.34 | 2021 | |
| Sanofi Pasteur INC. | $18.01 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $17.57 | 2025 | Dupixent |
| Bayer Healthcare Pharmaceuticals INC. | $16.85 | 2023 | |
| Edwards Lifesciences Corporation | $13.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nina Statile listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.